New drug aims to stop chemotherapy side effect before it starts
NCT ID NCT07243418
Summary
This study is testing whether a drug called hetrombopag can prevent or reduce severe drops in platelet counts (thrombocytopenia) caused by certain breast cancer treatments known as ADC drugs. It will enroll 72 breast cancer patients who are either starting ADC treatment or who previously experienced low platelets on it. The goal is to see if taking hetrombopag can keep platelet levels safer, potentially preventing treatment delays or complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.